Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3(7) of Directive 2001/83/EC1 (so called “hospital exemption”) must be manufactured under equivalente quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
News & Trends
Procurar
Recentes
- HTA Regulation – Commission selects first medical devices for joint clinical assessment
- PHARMACOVIGILANCE UPDATE | FDA E2B(R3) IMPLEMENTATION GUIDE — OCTOBER 2026
- updated PIC/S PI 006-4 guideline RECOMMENDATIONS ON QUALIFICATION AND VALIDATION
- Annual report of the Pharmacovigilance Inspectors Working Group for 2025
- European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
- ACT EU workplan 2026 – 2027
- Advice on ‘end-of-year’ submission dates for type I variations in 2026
- EMA UPDATE : COMPLIANCE with EU GMP Annex 22 and Artificial Intelligence Standards

